Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
© 2020 John Wiley & Sons Ltd..
BACKGROUND: Oncostatin M is upregulated in Crohn's disease inflamed intestinal mucosa, and has been suggested as a promising biomarker to predict responsiveness to anti-TNF therapy in patients with inflammatory bowel diseases.
AIM: To evaluate the suitability of serum oncostatin M as a predictive marker of response to infliximab in Crohn's disease.
METHODS: We included patients treated with infliximab monotherapy. All patients underwent colonoscopy at week 54 to evaluate mucosal healing. Serum oncostatin M and faecal calprotectin were measured at baseline and after 14 weeks of treatment. Mann-Whitney test was used to evaluate correlation of oncostatin M and faecal calprotectin at baseline and week 14 with mucosal healing at week 54. Their accuracy in predicting mucosal healing was assessed by area under the curve (AUC).
RESULTS: In a cohort of 45 included patients, 27 displayed mucosal healing. At both baseline and week 14, oncostatin M levels were significantly lower in patients with mucosal healing than in patients not achieving this endpoint (P < 0.001). Faecal calprotectin levels at week 14 were lower also in responders than nonresponders (P < 0.001). Oncostatin M values at baseline and week 14 were significantly associated (Spearman correlation = 0.92, P < 0.001). The diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing (AUC = 0.91) was greater than faecal calprotectin (AUC = 0.51, P < 0.001).
CONCLUSION: These results suggest that oncostatin M can predict the outcome of infliximab treatment. Compared with faecal calprotectin, the predictive capability of oncostatin M was appreciable at baseline, thus indicating oncostatin M as a promising biomarker for driving therapeutic choices in Crohn's disease.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2020 Sep;52(6):1080-1081. - PMID 33119166 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 52(2020), 2 vom: 17. Juli, Seite 284-291 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bertani, Lorenzo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
106956-32-5 |
|---|
| Anmerkungen: |
Date Completed 09.11.2020 Date Revised 09.11.2020 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2020 Sep;52(6):1080-1081. - PMID 33119166 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.15870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310861551 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310861551 | ||
| 003 | DE-627 | ||
| 005 | 20231225141018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.15870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310861551 | ||
| 035 | |a (NLM)32506635 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bertani, Lorenzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2020 | ||
| 500 | |a Date Revised 09.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2020 Sep;52(6):1080-1081. - PMID 33119166 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Oncostatin M is upregulated in Crohn's disease inflamed intestinal mucosa, and has been suggested as a promising biomarker to predict responsiveness to anti-TNF therapy in patients with inflammatory bowel diseases | ||
| 520 | |a AIM: To evaluate the suitability of serum oncostatin M as a predictive marker of response to infliximab in Crohn's disease | ||
| 520 | |a METHODS: We included patients treated with infliximab monotherapy. All patients underwent colonoscopy at week 54 to evaluate mucosal healing. Serum oncostatin M and faecal calprotectin were measured at baseline and after 14 weeks of treatment. Mann-Whitney test was used to evaluate correlation of oncostatin M and faecal calprotectin at baseline and week 14 with mucosal healing at week 54. Their accuracy in predicting mucosal healing was assessed by area under the curve (AUC) | ||
| 520 | |a RESULTS: In a cohort of 45 included patients, 27 displayed mucosal healing. At both baseline and week 14, oncostatin M levels were significantly lower in patients with mucosal healing than in patients not achieving this endpoint (P < 0.001). Faecal calprotectin levels at week 14 were lower also in responders than nonresponders (P < 0.001). Oncostatin M values at baseline and week 14 were significantly associated (Spearman correlation = 0.92, P < 0.001). The diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing (AUC = 0.91) was greater than faecal calprotectin (AUC = 0.51, P < 0.001) | ||
| 520 | |a CONCLUSION: These results suggest that oncostatin M can predict the outcome of infliximab treatment. Compared with faecal calprotectin, the predictive capability of oncostatin M was appreciable at baseline, thus indicating oncostatin M as a promising biomarker for driving therapeutic choices in Crohn's disease | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Oncostatin M |2 NLM | |
| 650 | 7 | |a 106956-32-5 |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Fornai, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Fornili, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Antonioli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenuti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Tapete, Gherardo |e verfasserin |4 aut | |
| 700 | 1 | |a Baiano Svizzero, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Mumolo, Maria Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Baglietto, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a de Bortoli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bellini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Marchi, Santino |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Blandizzi, Corrado |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 52(2020), 2 vom: 17. Juli, Seite 284-291 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:2 |g day:17 |g month:07 |g pages:284-291 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.15870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 2 |b 17 |c 07 |h 284-291 | ||